Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
about
Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyCardioprotection.Localized in vivo activation of a photoactivatable doxorubicin prodrug in deep tumor tissue.Extraction protocol and mass spectrometry method for quantification of doxorubicin released locally from prodrugs in tumor tissue.Thymol and Carvacrol Prevent Doxorubicin-Induced Cardiotoxicity by Abrogation of Oxidative Stress, Inflammation, and Apoptosis in Rats.Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesContinuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac OutcomesThe relevance of information generated by in vitro experimental models to clinical doxorubicin cardiotoxicity.Anthracycline cardiotoxicity.Oxidative stress induced by low-dose doxorubicin promotes the invasiveness of osteosarcoma cell line U2OS in vitro.Does anthracycline administration by infusion in children affect late cardiotoxicity?Protective effect of proanthocyanidins against doxorubicin-induced nephrotoxicity in rats.An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
P2860
Q24240568-8B121412-9256-4417-BE4E-20B24075AECEQ24243810-FAED3561-A961-4996-8F3D-9034618E837FQ33751247-6C40387D-1960-4EAB-9C3E-5B819AD1F7CDQ33812832-31571F09-B0EC-42D0-9009-35C8131DC5E4Q33946444-EDC15133-7F7D-4407-91AC-7A59AECDDAC9Q34494900-7E1B9F17-6D68-4134-BFB1-8BC02801427CQ34746933-AE7F6FC8-D9C1-455D-A3BA-DE5322BD8A90Q35583768-CBB9D057-A01C-46C6-B00F-8B0115C7A8DDQ36425761-050128BE-B44E-4C6A-889F-E4EFF5EAD13CQ36590959-D9CAF99F-7ECF-4EB4-B8B3-9071EB703B3DQ36624983-B4F388BD-1C5A-43C0-9008-02FB4C8D0D50Q38841629-68482701-8373-45F5-9D99-8CD6CCCF0D1EQ44776800-D1305D09-F712-4CF0-B63B-D7C275991F16Q48318998-4BF87BF1-83CA-435B-BBC4-B53CB7B36095Q48357803-0DA662DE-D24C-4DA6-98F9-CF3DC4CD3AC0Q58696664-262F83A5-FDAD-42E4-9424-E50C62463BB5
P2860
Doxorubicin cardiotoxicity in children: comparison of a consecutive divided daily dose administration schedule with single dose (rapid) infusion administration.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Doxorubicin cardiotoxicity in ...... apid) infusion administration.
@en
Doxorubicin cardiotoxicity in ...... tion schedule with single dose
@nl
type
label
Doxorubicin cardiotoxicity in ...... apid) infusion administration.
@en
Doxorubicin cardiotoxicity in ...... tion schedule with single dose
@nl
prefLabel
Doxorubicin cardiotoxicity in ...... apid) infusion administration.
@en
Doxorubicin cardiotoxicity in ...... tion schedule with single dose
@nl
P2093
P2860
P1476
Doxorubicin cardiotoxicity in ...... apid) infusion administration.
@en
P2093
P2860
P304
P356
10.1002/(SICI)1096-911X(199812)31:6<512::AID-MPO8>3.0.CO;2-4
P577
1998-12-01T00:00:00Z